Literature DB >> 20476859

Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA.

A Nakajima1, E Inoue, E Tanaka, G Singh, E Sato, D Hoshi, K Shidara, M Hara, S Momohara, A Taniguchi, N Kamatani, H Yamanaka.   

Abstract

OBJECTIVES: To investigate mortality, cause of death, and risk factors related to mortality in Japanese patients with rheumatoid arthritis (RA).
METHODS: The IORRA cohort is a large observational cohort established in 2000 at the Institute of Rheumatology, Tokyo Women's Medical University. Essentially, all RA patients were registered and clinical parameters were assessed biannually. For patients who failed to participate in subsequent surveys, simple queries were mailed to confirm survival. Standardized mortality ratios (SMRs) were calculated and mortality risk factors were analysed using a Cox proportional hazard model.
RESULTS: We analysed 7926 patients (81.9% females; mean age 56.3 ± 13.1 years; mean disease duration 8.5 ± 8.3 years) with RA who enrolled in IORRA from October 2000 to April 2007. During the observational period (35 443.0 person-years), 289 deaths were reported. Major causes of death included malignancies (24.2%), respiratory involvement (24.2%) including pneumonia (12.1%) and interstitial lung disease (ILD) (11.1%), cerebrovascular disease (8.0%), and myocardial infarction (7.6%). As death was not confirmed in all patients, the SMR was deduced to be between 1.46 [95% confidence interval (CI) 1.32-1.60] and 1.90 (95% CI 1.75-2.07) for all patients, between 1.45 (95% CI 1.22-1.70) and 1.70 (95% CI 1.45-1.97) for men, and between 1.46 (95% CI, 1.29-1.65) and 2.02 (95% CI 1.82- 2.24) for women. Factors associated with increased mortality included male gender, older age, worse physical disability, positive rheumatoid factor (RF), corticosteroid use, and presence of ILD.
CONCLUSION: The mortality of Japanese RA patients is comparable to that in previous reports from western countries, even though the causes of death were significantly different.

Entities:  

Mesh:

Year:  2010        PMID: 20476859     DOI: 10.3109/03009741003604542

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  32 in total

Review 1.  Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances.

Authors:  Wei-Ye Liu; Zhi-Bin Wang; Li-Chao Zhang; Xin Wei; Ling Li
Journal:  CNS Neurosci Ther       Date:  2012-06-12       Impact factor: 5.243

2.  Incidence of malignancy in Japanese patients with rheumatoid arthritis.

Authors:  Toru Yamada; Ayako Nakajima; Eisuke Inoue; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

3.  Comorbid conditions are associated with healthcare utilization, medical charges and mortality of patients with rheumatoid arthritis.

Authors:  Guang-Ming Han; Xiao-Feng Han
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

4.  Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment.

Authors:  Mio Akiyama; Taro Mawatari; Yasuharu Nakashima; Hisaaki Miyahara; Hisakata Yamada; Ken Okazaki; Jun-ichi Fukushi; Masakazu Kondo; Junji Kishimoto; Chinami Hashimura; Yukihide Iwamoto
Journal:  Clin Rheumatol       Date:  2015-08-21       Impact factor: 2.980

5.  Risk factors associated with the occurrence of hip fracture in Japanese patients with rheumatoid arthritis: a prospective observational cohort study.

Authors:  T Furuya; E Inoue; T Hosoi; A Taniguchi; S Momohara; H Yamanaka
Journal:  Osteoporos Int       Date:  2012-07-17       Impact factor: 4.507

6.  Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis.

Authors:  Ayako Nakajima; Eisuke Inoue; Yoko Shimizu; Akiko Kobayashi; Kumi Shidara; Naoki Sugimoto; Yohei Seto; Eiichi Tanaka; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka
Journal:  Clin Rheumatol       Date:  2014-07-31       Impact factor: 2.980

7.  Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis.

Authors:  Dam Kim; Soo-Kyung Cho; Chan-Bum Choi; Jung-Yoon Choe; Won Tae Chung; Seung-Jae Hong; Jae-Bum Jun; Young Ok Jung; Tae-Hwan Kim; Tae-Jong Kim; Hye-Soon Lee; Joo-Hyun Lee; Jisoo Lee; Shin-Seok Lee; Dae-Hyun Yoo; Bo Young Yoon; Jin Woo Song; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2017-07-26       Impact factor: 2.631

Review 8.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  Neurological improvement and prognosis after occipito-thoracic fusion in patients with mutilating-type rheumatoid arthritis.

Authors:  Tetsu Tanouchi; Takachika Shimizu; Keisuke Fueki; Masatake Ino; Naofumi Toda; Yasunori Tatara; Nodoka Manabe
Journal:  Eur Spine J       Date:  2012-07-27       Impact factor: 3.134

Review 10.  Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?

Authors:  George E Fragoulis; Katerina Chatzidionysiou
Journal:  Clin Rheumatol       Date:  2019-12-13       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.